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Polysubstance Abuse–Vulnerability Genes: Genome Scans for Association,
Using 1,004 Subjects and 1,494 Single-Nucleotide Polymorphisms
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Johns Hopkins University, Baltimore
Strong genetic contributions to drug abuse vulnerability are well documented, but few chromosomal locations for
human drug-abuse vulnerability alleles have been confirmed. We now identify chromosomal markers whose alleles
distinguish drug abusers from control individuals in each of two samples, on the basis of pooled-sample microarray
and association analyses. Reproducibly positive chromosomal regions defined by these markers in conjunction with
previous results were especially unlikely to have been identified by chance. Positive markers identify the alcohol
dehydrogenase (ADH) locus, flank the brain-derived neurotropic factor (BDNF) locus, and mark seven other regions
previously linked to vulnerability to nicotine or alcohol abuse. These data support polygenic contributions of
common allelic variants to polysubstance abuse vulnerability.
Introduction
Problems from drug abuse permeate each branch of med-
icine. Prevention and treatment strategies remain far from
optimal. Drug abuse vulnerability is a complex trait with
strong genetic influences documented in numerous family
and twin studies (Cadoret et al. 1986, 1995; Grove et al.
1990; Pickens et al. 1991; Goldberg 1993; Gynther et al.
1995; Uhl et al. 1995, 1997, 1999; Tsuang et al. 1996,
1998, 1999; Woodward 1996; Kendler and Prescott
1998; Merikangas et al. 1998; Kendler et al. 1999; Stall-
ings et al. 1999; True et al. 1999a, 1999b; Karkowski et
al. 2000). Much of the genetic vulnerability to abuse of
different legal and illegal addictive substances is shared
(Kendler and Prescott 1998; Tsuang et al. 1998; Kendler
et al. 1999; True et al. 1999b; Karkowski et al. 2000),
and many abusers use multiple addictive substances (Sub-
stance Abuse and Mental Health Services Administration
1995). Understanding the genetic bases of drug abuse vul-
nerability and identifying the particular allelic variants
that contribute to this vulnerability can improve our un-
derstanding of human addictions and can assist efforts to
match vulnerable individuals with the prevention and
treatment strategies most likely to work for them.
Linkage-based genome scans for legal addictions have
been reported by Long et al. (1998), Reich et al. (1998),
Straub et al. (1999), and Faroud et al. (2000). However,
few positive findings from any one study were replicated
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in any other study. With this lack of convergent results,
these scans have failed to provide evidence for the ex-
istence of common allelic variants, across different hu-
man samples, that could predispose to vulnerability to
substance abuse.
We approach the problem of identifying chromoso-
mal regions and genes that contain allelic variants that
predispose to the abuse of illegal substances by asso-
ciation genome scanning. Association approaches do
not require the participation of family members and
thus increase the representativeness of our sample, since
few abusers allow us to contact their family members.
Association studies can gain more power from higher
genomic marker densities than can linkage approaches
(Risch and Merikangas 1996; Cervino and Hill 2000;
Schork et al. 2000; Sham et al. 2000). High marker
densities reduce the chance of false-positive results due
to unintended ethnic mismatching of the disease and
control populations when allele frequencies at many loci
in the disease group are indistinguishable from those in
control subjects. Association studies can identify smaller
genomic regions likely to harbor candidate pathogenic
allelic variants than can linkage-based methods, speed-
ing searches for the specific allelic variants that directly
contribute to disease vulnerability. Association studies
foster pooling strategies that can allow high marker
densities to be determined with the maximum possible
preservation of confidentiality, since no individuals’ gen-
otypes are identified (Barcellos et al. 1997; Hacia et al.
1999; Germer et al. 2000).
We compare results from unrelated individuals who
have substantial histories of illegal substance use and/
or dependence with results from matched samples of
individuals who have no significant lifetime use of any
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addictive substance. Relative allelic frequencies of 1,494
single-nucleotide polymorphism (SNP) markers in
abuser and control European American samples are as-
sessed. Allelic frequencies for the SNPs that show ten-
tative positive results in the European American sample
are tested in a sample of African American abusers and
control individuals. We focus analyses on SNPs in chro-
mosomal regions where (a) two nearby SNPs display
different allelic frequencies in both European American
and African American abusers versus control subjects
or (b) one or more of these reproduced positive SNPs
are located near markers previously linked with depen-
dence on legal substances (Long et al. 1998; Reich et
al. 1998; Straub et al. 1999; Foroud et al. 2000). These
data and their convergence with prior results support,
for the first time, contributions of common allelic var-
iants to polygenic models of genetic vulnerability to
polysubstance abuse. They identify several chromoso-
mal regions that are candidates for harboring common
gene variants that alter vulnerability to substance abuse.
Finally, they also identify strong candidate genes in sev-
eral of these regions.
Material and Methods
Research volunteers provided informed consent under as-
surances of confidentiality, chose the extent of family
member contacts that they would authorize, and were
reimbursed for time spent. They self-reported their eth-
nicity and drug histories, using the drug use survey (DUS)
(Smith et al. 1992; Persico et al. 1996) and diagnostic
interview schedule (DIS). Some results were compared
with those obtained separately from family members en-
rolled in a family pedigree study (G. R. Uhl, J. Hess, D.
Walther, and C. Cantoneggi, unpublished data). For ex-
traction of DNA, 10 ml of blood was obtained.
Two hundred thirty-nine “control” unrelated indi-
viduals of self-reported European American ancestry
had no significant lifetime history of use of any addictive
substance, average age 32 years, and 0 or 1 DUS total
drug use scores. Four hundred fifteen unrelated “abus-
ers” averaged 30.6 years old and scored 3 on the total
drug use scale and/or demonstrated dependence, ac-
cording to DSM-III-R criteria, on at least one illegal
abused substance. Individuals with intermediate levels
of substance use (2 DUS scores) who did not reach
DSM-III-R dependence criteria for at least one illegal
substance were excluded from this study. Average total
drug use scores were 2.8 for abusers and 0.57 for con-
trol individuals.
Individuals of self-reported African American descent
were also studied. Two hundred fifty-two abusers av-
eraged 35.9 years of age and had mean total drug use
scores of 2.9. Ninety-nine control individuals averaged
36.5 years of age and displayed average total drug use
scores of 0.51.
Leukocyte genomic DNA was prepared as described
elsewhere (Smith et al. 1992; Persico et al. 1996). DNA
concentrations were quantitated by spectrophotometry
and Hoechst dye fluorescence and were diluted to 10
ng/ml. Pools were made by combination of DNAs from
20 individuals in equal amounts. For reproducibility
tests, replicate DNA pools were constructed for each
determination.
Multiplex PCR reactions were performed as 24 sep-
arate 12-ml reactions in 96-well microtiter plates ac-
cording to the manufacturer’s instructions (Affymetrix).
DNA from individuals or pools was amplified in 24
separate reactions that each contained 6 ng of DNA
from each individual and 84 multiplex PCR primer
pairs. Primary PCR products were subjected to labeling
PCR as described by Affymetrix. The 24 labeled PCR
samples corresponding to each genomic DNA sample
were then pooled, diluted in hybridization buffer, heated
to 95C, cooled to 4C, and hybridized with Affymetrix
HuSNP GeneChip microarrays at 45C for 18 h. Arrays
were washed with two changes of 6# sodium chloride/
sodium phosphate EDTA buffer pH 7.4 (SSPE), 0.01%
Triton at 25C and then with six changes of 4# SSPE,
0.01% Triton at 35C. DNA hybridized to the washed
microarrays was stained using 2 mg/ml phycoerythrin-
conjugated streptavidin in 6# SSPE, 0.01% Triton, 0.5
mg/ml BSA at 25C for 30 min. Stained arrays were
washed with four changes of 6# SSPE/0.01% Triton
at 25C and then were scanned using a GeneArray Laser
Scanner (Hewlett-Packard).
Genotype calls for individual DNAs were made using
Affymetrix GeneChip software (3.3). Allelic frequencies
in pooled DNA samples were assessed on the basis of
data from the “.cell” files and of an algorithm that
averaged the hybridization intensity signals from the
8–16 features per chip that provided perfectly comple-
mentary hybridization to the alleles termed “A” or “B”
for each SNP. First, the “background,” determined as
the average of the lowest 5% of intensity values on each
microarray, was subtracted from the fluorescence inten-
sity of each cell of that microarray. Second, background-
corrected values were normalized by dividing each value
by the average of the highest 5% of intensity values on
each microarray. Third, normalized hybridization in-
tensities from the microarray elements that corre-
sponded to the perfect match “A” and perfect match
“B” alleles for each SNP were each averaged. Fourth,
“A/B ratios” were determined by dividing average nor-
malized A values by average normalized B values. Fifth,
arctangent transformations were applied to each ratio
to improve combination of data from experiments with
different absolute intensity values. Lastly, “arctan A/B”
ratios for abusers were then divided by “arctan A/B”
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ratios for control individuals to form an abuser/control
ratio, our primary analysis.
Means of three replications for each experiment iden-
tified SNPs with abuser/control hybridization ratios in
the top and bottom 5% of the distribution for the Eu-
ropean American abuser versus control comparisons.
Reproducibility of these “candidate positive” SNPs was
sought by asking if they were also in the upper or lower
7.5% of the distribution of hybridization ratios in data
from two replications in African American abuser ver-
sus control samples. Physical locations of these reprod-
ucibly positive SNPs and of markers linked to alcohol
or nicotine dependence in previous studies were sought
in Mapviewer (build 22 [May 2001]) and related NCBI
programs by two independent investigators. Additional
locations were sought in Mapviewer build 24 [Septem-
ber 2001]).
Allele calls from individual DNA samples were also
compared with results from pooled DNAs from the
same individuals. Regression analyses compared allele
frequencies for SNPs that were called in most of the
individuals studied. Test-retest variability was studied
in replicated microarray results from DNA pools pre-
pared in duplicate or triplicate from the same DNA
stocks from the same individuals. Using Monte Carlo
simulations and the C computer language, we compared
results with those expected by chance. For the initial
results of SNPs that were positive in both European
American and African American samples, 100,000
Monte Carlo trials were carried out. In each trial, 149
markers (5%5% of 1,493) were sampled with re-
placement, and, subsequently, 222 (7.5%7.5% of
1,493) were sampled with replacement from all of the
1,493 markers. The number of markers common to
both samples were then determined. In only 11 of these
trials did we find 42 markers in common (Pp
). To model the chance probabilities of obtaining.00011
positive markers as close to each other as the three clos-
est pairs identified here, we used 1 million simulation
trials in which 42 markers were randomly positioned
on a 3.2 billion–bp genome and pairwise distances be-
tween each marker pair were determined. We assessed
the number of simulations in which the smallest distance
was !0.7 Mb, the second smallest distance was !1.5
Mb, and the third smallest distance was !2.2 Mb (Ma-
pviewer 22 distances modeled; corresponding build 24
distances are 0.2, 2.8, and 6.6Mb). Tomodel the chance
probabilities of obtaining positive markers as close to
markers previously reported to be linked to ethanol or
nicotine addictions, we used 1100 million simulation
trials in which 61 markers were randomly positioned
on a 3.2 billion–bp genome, 41 markers were placed
randomly on the same genome, and pairwise distances
between each marker pair (consisting of one member
of the first set and one member of the second set) were
determined. We assessed the number of simulations in
which at least seven of the distances were !1 Mb (Ma-
pviewer 22 distances modeled; corresponding build 24
distances are 0, 0.1, 0.4, 0.4, 0.4, 2.3, and 2.7 Mb).
Linkage disequilibrium was assessed using Arlequin for
data from individual genotypes determined for 20 con-
trol subjects.
A dinucleotide repeat in the an intron close to the 5′
end of themain coding exon of brain-derived neurotropic
factor (BDNF) (Krebs et al. 2000) was amplified using
6-FAM labeled oligonucleotides 5′-GCCACTTTATCTC-
CTCCAGT (forward) and 5′-AGCACTAGCTGCCTAT-
TCCA (reverse) and AmpliTaqGold polymerase and buf-
fer in an initial 95C denaturation for 10 min, followed
by 35 cycles of 94C for 30 s, 60C for 30 s, and 72C
for 45 s, and then a final extension at 72C for 10 min.
Markers flanking the BDNF locus, D11S2001 and
GATA25B04, were amplified using oligonucleotides 5′-
TTGGTTAAGAATGGAAATTCC-3′ (forward) and 5′-
TGAAATCACCTAATGGTGGG-3′ (reverse), as well as
5′-TAAGGCACACATCTTCAGCC-3′ (forward) and 5′-
GTGTCCTACCAAATAGAAACTTCC-3′ (reverse), re-
spectively, under the same conditions. Alleles were re-
solved using 10% denaturing polyacrylamide gels, an
ABI 373 sequencer, and gene-scan software.
Results
Each research volunteer who was offered participation
in the study accepted, although !20% provided per-
mission for family-member contacts. Sibs’ and parents’
drug-use histories for each member of 100 pedigrees
were concordant with proband ratings 81% and 73%
of the time, respectively. DUS quantity/frequency esti-
mates, when compared with addiction-severity index
(ASI) ratings, revealed that no individual with a DUS
score of 0 reported alcohol, cocaine, heroin, cannabis,
or nicotine “use more than 5 times” by ASI and that
199% of the individuals who scored 3 on the DUS
reported that they “used more than 5 times” by ASI.
Good correspondence between DUS 3 ratings and
DSM-III-R criteria for abuse and/or dependence diag-
noses is also documented in this population (Smith et
al. 1992; Persico et al. 1996).
Pooled SNP genotyping was performed with accept-
able reproducibility and evidence for validity. In three
replicate experiments, mean hybridization ratio (arctan
A/B) values ( SEM) were 27.2  2.1 in European
American control and 27.1 1.9 in abusers. SNPs for
which both sense and antisense oligonucleotides provide
two independent assessments of hybridization of the
same mixed PCR product probe to the same microar-
rays displayed correlations of .96 between sense and
antisense hybridization values. There were correlations
of .8–.9 between the hybridization ratios for pools and
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the ratio between the frequencies of A and B alleles
determined individually for each pool member (loci for
which we determined these correlations are available at
our FTP site). Genotype calls for individuals from the
Centre d’Etudes Polymorphisms Humaine show a cor-
relation of 1.95 with genotypes determined by sequenc-
ing by Affymetrix. Abuser/control hybridization ratios
for the 1,494 SNPs examined here fell into nearly Gaus-
sian distributions, with mean values close to 1, provid-
ing no evidence for overall ethnic mismatches between
abuser and control populations.
Candidate positive markers, the 5% of SNPs with
greatest and smallest abuser/control ratios in European
Americans (11.119 or !0.893; see fig. 1) were tested for
their ability to also provide differences between allelic
frequencies between abuser and control populations
from the African American sample. Of these 150 can-
didate positive markers, 42 were “reproducibly posi-
tive,” with values lying in the upper or lower 7.5% of
the African American data (table 1). Chance would have
made 22 of the original markers display these features.
Monte Carlo simulations suggested that the probability
of randomly distributed markers producing 42 mark-
ers common to the two populations was .00011.
When the positions of these 42 reproducibly positive
markers were determined, one pair of independent
markers were adjacent to each other, one other pair of
apparent SNPs actually queried the same underlying
SNP, and a pair on chromosome 11 flanked a strong
candidate-gene locus. Monte Carlo simulations indi-
cated a .043 probability that the members of three clos-
est marker pairs would lie at least as close to each other
as they do here by chance (Mapviewer, build 22; Pp
for build 24 positions)..036
The positive chromosome 4 markers WIAF-3818 and
WIAF-3821 both display positive abuser/control hy-
bridization ratios in European American and African
American samples. These WAIF markers use different
oligonucleotides to amplify overlapping sequences that
identify the same sequence tagged site, stsG67686; this
congruent result thus helps to validate the technique
used here.
Nearby reproducibly positive markers on chromo-
some 11, WIAF-2046 and WIAF-1949, are located at
Mapviewer build 22 coordinates 25.9 and 28.08 Mb,
respectively. The most strikingly positive SNP, WIAF-
2046, borders the location (25.9 Mb) of the strong can-
didate gene encoding BDNF (Jones and Reichardt 1990;
Maisonpierre et al. 1991; Shintani et al. 1992; Timmusk
et al. 1993; Horger et al. 1999; Lyons et al. 1999; Krebs
et al. 2000). This gene contains a dinucleotide-repeat
polymorphism located close to the 5′ end of the gene’s
main coding exon (Krebs et al. 2000). In initial studies
with sample pools, this BDNF gene marker also dis-
played association with drug-abuse vulnerability. The
long forms of this repeat were found with 21.3%
frequency in the 12 pooled samples of the 240 Eu-6%
ropean American individuals free from substance abuse
and in of the 20 pooled samples of 40016.3% 2%
drug abusers (mean  SEM of three repeated compar-
isons, differences between abuser and control Pp
, t-test). Simple sequence–repeat markers that flank.001
WIAF-2046 and WIAF (and thus flank this locus),
D11S2001 and GATA25B04, display statistically sig-
nificant values, ranging from 0.3 to 1, for their dif-′D
ferent alleles.
The reproducibly positive markers on chromosome
12, WIAF-364 and WIAF-3624, lie within ∼0.2 Mb of
each other and flank genes, including that for the T6J
protein, as well as several EST clusters (Mapviewer
builds 22 and 24). These display strong linkage dise-
quilibrium, with values ∼1 in control subjects.′D
The positions of these reproducibly positive SNPs
from the current study can also be compared with lo-
calizable positions of 61 of the microsatellite markers
that were nominally positive in at least one linkage
study of alcohol or nicotine dependence (Long et al.
1998; Reich et al. 1998; Straub et al. 1999; Foroud et
al. 2000). Nine of these markers lie in six regions within
2 Mb of the location of one of the confirmed positive
SNPs in the current data set (Mapviewer build 22).
Seven of these nine lie within 1 Mb of one of these SNPs
(table 1; Mapviewer build 22; in build 24, five of them
are within that distance). Monte Carlo simulations in-
dicate that nine randomly distributed microsatellite
markers would lie this near to one of the confirmed
positive SNP markers in !1 in 108 simulation trials (Ma-
pviewer build 22; for build 24 positions).P ! .006
D3S3053, linked to alcoholism by Long et al. (1998),
is located 0.4–1 Mb from WIAF-452, a marker re-
producibly associated in the current study with poly-
substance abuse and is positioned near the phospholi-
pase D1 gene. D4S1627 is linked to alcoholism by Long
et al. (1998) and located at 51.4 Mb on chromosome
4 within 0.1–0.2 Mb of the reproducibly positive
marker WIAF-452. These markers lie near genes en-
coding ras and GABAA receptor–family members.
ADH3 and D4S2457—as well as D4S2457’s equiv-
alent, D4S1647—have been linked to alcoholism by two
different groups (Long et al. 1998; Reich et al. 1998).
These markers lie near WIAF-2765, a reproducibly pos-
itive SNP from the current study (Mapviewer build 22),
and near the alcohol dehydrogenase gene cluster. Al-
tered risk of alcoholism and/or effects on alcohol me-
tabolism from allelic variants at ADH3 or ADH2 have
been reported in several studies (Osier et al. 1999; Bor-
ras et al. 2000).
D9S319 is linked to alcoholism (Long et al. 1998)
and is positioned at 28.4 and 31.4 Mb (Mapviewer
build 22). These positions flank the 30.3–30.8 Mb (Ma-
Figure 1 Chromosome-by-chromosome distribution (labels 1–22 and X) of abuser/control ratios (y-axis) for SNPs positioned according
to their average radiation-hybrid chromosomal distance in centimorgans (x-axis). Abuser/control ratios shown are from the European American
sample. Red symbols indicate SNPs with results in the upper or lower 5% of the distribution of values. Labeled symbols indicate SNPs with
outlying abuser/control values in both European American and African American samples. Green symbols indicate the positions of reproducibly
positive SNPs with adjacent chromosomal positions, on the basis of NCBI Mapviewer coordinates.
1295
Table 1
Positions of SNP Markers Displaying Reproducibly Positive Association with Polysubstance Abuse in
the Current Study and of SSLPs Nominally Positive in Prior Linkage Studies of Alcohol or Nicotine
Dependence
CHROMOSOME
AND WIAF
OR SSLP
NUMBER
DISTANCE
SUBMITTED
SEQUENCE
NUMBER
OR REFERENCE
ABUSER/CONTROL
RATIO
Averaged
Radiation
Hybrid
Mapviewer
Build 22
Mapviewer
Build 24
European
American
African
American
1:
D1S548 5.2 7.1 Reich et al. 1998
WIAF-944 69 30.1 32.2 3043 1.23 1.41
D1S1598 33.2 38.6 Reich et al. 1998
D1S532 82.6 80.8 Reich et al. 1998
D1S1588 109.5 95.6 Reich et al. 1998
D1S1592 118.3 127.8 Reich et al. 1998
WIAF-1018 208.6 184.3 177 3117 .89 1.22
WIAF-952 242.2 194.7 211.2 3051 1.3 1.25
2:
D2S114 134.1 129.5 Straub et al. 1999
D2S1326 142.5 135 Straub et al. 1999
D2S426 197.3 185.2 Reich et al. 1998
WIAF-1942 124.7 209.6 208.1 3487 .84 1.38
WIAF-1700 248.3 234.8 229.7 2052 1.2 1.31
3:
D3S2403 16.1 15.9 Long et al. 1998
WIAF-1765 44.5 24.5 27.7 3312 1.12 1.4
D3S2432 29.5 32.4 Long et al. 1998
WIAF-4560 125 50.9 54.3 19367 .84 .82
WIAF-1473 143.3 126.6 125.4 1092 1.14 1.22
WIAF-3407 135.3 130.4 133.8 19294 1.12 1.31
D3S1746 164.1 156.5 Long et al. 1998
D3S1763 175.8 172.9 Long et al. 1998
D3S3053 184.4 176.6 Long et al. 1998
WIAF-847 187.1 185.4 177 2948 .79 .78
WIAF-250 207.2 191.3 191.3 2605 .83 .72
4:
D4S2382 37.3 25.1 Long et al. 1998
D4S2632 44.3 36.4 Long et al. 1998
D4S1647 109 37.4 Long et al. 1998
D4S2457 109 37.4 Reich et al. 1998
D4S174 49.6 41.9 Long et al. 1998
D4S2456 81.1 43.5 Long et al. 1998
D4S1627 51.4 45.8 Long et al. 1998
WIAF-452 60.9 51.6 45.9 2739 1.16 1.57
D4S1645 66.4 60.7 Long et al. 1998
D4S244 71.5 64.2 Reich et al. 1998
D4S2393 81.8 74.3 Reich et al. 1998
WIAF-2114 98.5 93.8 83.4 1227 .81 .71
WIAF-373 100 102.8 90 2688 1.34 1.44
ADH3 107.1 97 Reich et al. 1998
D4S3256 118.6 104.5 Long et al. 1998
D4S3240 116.8 106.6 Long et al. 1998
WIAF-2765 109.7 110.7 110.9 19501 .78 .73
WIAF-3818 125.8 139 122.6 1879 .84 1.29
WIAF-3821 127.8 139 122.6 1882 .85 1.63
5:
WIAF-3575 62.8 54 49.8 1636 1.19 1.32
WIAF-1869 81.5 68.3 69.5 3414 .86 1.32
D5S2501 105.6 105.9 Long et al. 1998
(continued)
Table 1 (continued)
CHROMOSOME
AND WIAF
OR SSLP
NUMBER
DISTANCE
SUBMITTED
SEQUENCE
NUMBER
OR REFERENCE
ABUSER/CONTROL
RATIO
Averaged
Radiation
Hybrid
Mapviewer
Build 22
Mapviewer
Build 24
European
American
African
American
6:
WIAF-1567 20.5 16.9 12.1 1124 1.12 1.56
WIAF-2177 41.9 37.7 36.4 1290 1.22 1.28
D6S1018 51.4 51.2 Reich et al. 1998
7:
D7S531 2.1 2.9 Long et al. 1998
D7S1793 49.2 50.3 Reich et al. 1998
WIAF-1680 126.5 104.6 104.6 1168 .85 1.25
D7S1809 127.4 121.1 Reich et al. 1998
8:
D8S549 14.9 15.7 Reich et al. 1998
D8S280 20.8 20.6 Reich et al. 1998
WIAF-1291 107 100.1 93.6 934 1.23 1.25
WIAF-989 147.7 131.3 130.5 3088 .89 .75
9:
WIAF-1900 49.8 30.3 28.5 3445 1.16 1.27
D9S319 28.3/31.4 30.8 Long et al. 1998
WIAF-3477 125.8 108.6 109.9 1538 .85 1.35
10:
D10S1435 2.2 2.1 Long et al. 1998
WIAF-3336 85.6 52.5 60.3 19256 1.17 .77
D10S677 102.4 98 Straub et al. 1999
D10S1239 108.7 105.6 Straub et al. 1999
WIAF-268 137.3 114.4 109.5 19487 1.18 1.21
D10S2469 114.4 109.5 Straub et al. 1998
11:
D11S1984 1.4 .3 Long et al. 1998
D11S2368 15.3 17.8 Long et al. 1998
AFM333TH1 17.7 17.1/18.1 Reich et al. 1998
WIAF-2046 39.1 25.9 25.5 3585 1.28 1.36
WIAF-1949 40 28.1 28.3 3494 1.18 1.47
D11S1392 35.4 34.4 Long et al. 1998
D11S976 128.1 122.4 Long et al. 1998
D11S2359 144.8 140.5 Reich et al. 1998
12:
D12S393 104.1 100.7 Reich et al. 1998
WIAF-364 153.2 133.9 129.3 2681 .83 .71
WIAF-3624 146.3 134.6 129.1 1685 .85 1.22
D12S1045 140 136 Reich et al. 1998
13:
D13S321 58.2 56.1 Reich et al. 1998
D13S762 96.5 90.8 Reich et al. 1998
WIAF-4520 29.9 94.8 93.5 19336 1.13 1.42
WIAF-2555 96.6 91.3 114.1/115.5 2068 1.13 .78
D13S285 92.2 115.1 Long et al. 1998
WIAF-600 80.8 102.5 101.5 2197 .86 1.23
D13S895 111.5 110.6 Long et al. 1998
15:
D15S153 65.2 62.5 Long et al. 1998
D15S642 99 99 Reich et al. 1998
(continued)
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Table 1 (continued)
CHROMOSOME
AND WIAF
OR SSLP
NUMBER
DISTANCE
SUBMITTED
SEQUENCE
NUMBER
OR REFERENCE
ABUSER/CONTROL
RATIO
Averaged
Radiation
Hybrid
Mapviewer
Build 22
Mapviewer
Build 24
European
American
African
American
16:
D16S675 9.13 7 Reich et al. 1998
GATA5H07 NA NA Long et al. 1998
D16S422 84.4 86.1 Straub et al. 1999
17:
D17S1308 1.7 .2 Long et al. 1998
WIAF-3343 77 61.9 67.4 1416 .88 .8
D17S2059 70.7 71.3 Straub et al. 1999
D17S1535 74.8 75.6 Long et al. 1998
18:
D18S869 21.4 19 Straub et al. 1999
WIAF-303 65.9 51.1 50.7 2127 1.14 1.52
D18S844 76.2 77.4 Long et al. 1998
19:
WIAF-2426 35 NA NA 3698 1.32 1.46
D19S49 40.7 44.1 Reich et al. 1998
21:
WIAF-4514 43 31.7 NA 19393 1.14 1.21
22:
WIAF-3065 43.2 42.8 43.3 19273 1.12 1.55
X:
WIAF-2589 156.1 117.4 123.1 3824 1.13 1.28
DXS8061 138.4 147.5 Straub et al. 1998
WIAF-1743 187.7 138.8 147.8 3290 .89 .75
Not placed:
D4S3242 NA Long et al. 1998
NOTE.—Reproducibly positive SNPs from the current study and simple sequence–length repeat markers
displaying nominally significant linkage in prior affected sib-pair linkage studies of alcohol or nicotine
dependence. Reproducibly positive SNPs with abuser/control ratios in the upper or lower 5% of values in
the European American sample and in the upper or lower 7.5% in the African American sample are listed
here. SNP markers are identified by WIAF numbers (column 1). Markers are listed along with their
chromosomal assignments (column 1), averaged radiation hybrid distances (column 2) in cM, ratio of A/
B alleles in substance abusers divided by those for control individuals in the European American (column
7) and African American (column 8) sample pools (see Methods). Mapviewer chromosomal positions
(expressed in Mb) of SNPs use build 22 and build 24. Markers whose data are shown in boldface italics
lie near other positive markers in build 24. Two pairs of markers, D4S2457/D4S1647 and WIAF-3818/
WIAF-3821, sample the same two underlying polymorphisms. Underlining indicates differently named
assays that sample the same underlying sequence variations.
pviewer builds 22 and 24) location for WIAF-1900 that
was reproducibly positive in the current study. This
marker is near an interesting gene encoding a phospho-
lipase A2–activating protein.
D10S2469, a chromosome 10 marker located at
114.4–109.5 Mb and linked to nicotine dependence
(Mapviewer builds 22 and 24) (Straub et al. 1999) has
a position difficult to distinguish from that of the re-
producibly positive SNP WIAF-268. D13S285, a 91.3-
to 115.1-Mb marker linked to alcoholism (Long et al.
1998) lies near the reproducibly positive SNP WIAF-
2555, located at 92.2–114.1/115.5 Mb (Mapviewer
build 22 and two locations in build 24). Genes encoding
the endothelin B receptor and several meiotic proteins
are nearby. DXS8061 is linked to nicotine dependence
with a modestly positive LOD score and is located on
chromosome X at 138.4–147.5 Mb (Mapviewer builds
22 and 24) (Straub et al. 1999). WIAF-1743 is also
located at 138.8–147.8 Mb, near genes that encode zinc
finger proteins.
Discussion
This initial genome-scanning study of polysubstance-
abuse vulnerability provides 41 candidate chromosomal
regions nominated in a European American sample and
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reproduced in an African American sample. A candidate
region on chromosome 12 contains two closely adjacent
positive SNP markers. Two markers on chromosome 11
identify the BDNF locus where initial studies, with ad-
ditional locus-specific markers, also identify association.
Other regions—on chromosomes 3, 4, 10, 13, and
X—are sites for both positive SNPs from the current
data and positive markers from previous linkage studies
of alcohol or nicotine dependence. These results are un-
likely to all be due to chance. They identify regions con-
taining candidate genes that have also been implicated
in other populations, in studies of the genetics of vul-
nerability to addiction.
Clinical and laboratory results provide evidence for
the reliability and validity of this approach. The extent
of study participation and the good fit between clinical
histories supplied by different family members support
the validity and representativeness of the clinical sample
studied here. Features of the SNP-analysis method used
here also indicate sufficient reliability and validity to
test our working hypotheses. Test-retest correlations,
the correlations between sense and antisense hybridi-
zation patterns, and the correlations between pooled
and individually obtained genotypes each support the
pooling strategy used here. Finding reproducible posi-
tive results from two sets of oligonucleotides that in-
terrogate the same sequence-tagged site further validates
the current technique. The extent to which markers are
positive in both our European American sample and
our African American one, the extent to which some of
these doubly positive markers lie next to each other, and
the extent to which they are located next to markers
defined in previous studies of legal addictions are each
greater than is likely to be due to chance. These obser-
vations each add to confidence in the methods used.
The chromosome 11 region between WIAF-2046 and
WIAF-1949 contains the strong candidate-gene locus
that encodes BDNF. Long alleles of the BDNF dinucle-
otide repeat found in the intron just 5′ to the main coding
exon are also associated in our sample with vulnerability
to polysubstance abuse. These same alleles distinguish
French substance-abusing schizophrenic patients from
schizophrenic individuals who are free of substance dis-
orders (Krebs et al. 2000). These data from several pop-
ulations add to other genomic and neurobiological in-
formation supporting the likelihood that BDNF variants
could contribute to vulnerabilities to polysubstance
abuse. This locus displays a wealth of variation (Tim-
musk et al. 1993). BDNF influences dopamine and se-
rotonin neurotransmitters that are heavily linked to ad-
diction (Dluzen et al. 1999; Horger et al. 1999; Lyons et
al. 1999; Kernie et al. 2000). Cocaine preference and
alcohol consumption can be altered with BDNF admin-
istration or heterozygous gene deletion (Dluzen et al.
1999; Horger et al. 1999; Lyons et al. 1999; Kernie et
al. 2000). Although the exact distances fromWIAF-2046
to BDNF and from BDNF to WIAF-1949 vary in recent
Mapviewer versions, there is substantial linkage dise-
quilibrium between the GATA25B04/D11S2364 and
D11S2001 markers that flank the BDNF/WIAF-2046/
WIAF-1949 interval (significant values 0.31;′ 2D x p
; ; ). As we study this region further,17.9 np 54 P ! .001
we will be able to determine whether variation in BDNF
and/or adjacent genes contributes to our initial obser-
vations of association.
Other reproducibly positive SNPs lie near markers
previously linked to legal addictions much more often
than is likely by chance. Each of the regions defined by
these convergent data sets contains interesting candidate
genes worthy of further study. Striking findings at the
chromosome 4 region of ∼107–110.7 Mb (Mapviewer
build 22) containing WIAF-2765, D4S2457/ D4D1647,
and ADH3 each fit with the large body of evidence that
alcohol dehydrogenase gene variants alter predisposi-
tion to alcohol dependence. Other studies have also
identified altered risk of alcoholism and/or effects on
alcohol metabolism from ADH allelic variants (Xu et
al. 1988; Osier et al. 1999; Borras et al. 2000). Our
current data, however, provide the first association be-
tween these loci and vulnerability to illegal substance
abuse. Primary and/or secondary effects of ADH alleles
on polysubstance abuse are possible. For example, al-
cohol could serve as a gateway drug, and/or smoking
could interact with ADH activities (Marselos et al.
1991; Bhagwat et al. 1998).
These initial genome-scanning studies of polysubst-
ance abuse–vulnerability genes provide an approach
that can be extended. Modeling studies demonstrate in-
creasing power of association approaches with increas-
ing marker densities (D. Naiman and G. R. Uhl, un-
published data). Studying additional markers in these
and other samples will help us to identify more of the
alleles that distinguish individuals with substance vul-
nerabilities from those who remain free from substance
abuse. Although few studies may individually provide
sufficient power to unequivocally identify disease alleles
(Lander and Kruglyak 1995), careful nomination and
confirmation in multiple clinical samples provides
stronger and stronger cumulative assurance against
false-positive or poorly generalizable results. We report
the current results and their congruence with others’
data in this spirit.
The current data and their convergence with others’
results now provide support for the likelihood that com-
mon allelic variants play significant roles in vulnerabil-
ities to substance abuse. Such support was not evident
in prior linkage studies that did not identify similar
linked chromosomal regions. Even common allelic var-
iants, however, could each provide distinct influences
on different clinical features of the disorder. Vulnera-
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bility alleles could also provide pleiotropic manifesta-
tions in other behavioral disorders. As the alleles that
contribute to vulnerability to substance abuse are elu-
cidated in more repeated studies, identification of the
ways in which they change specific features of vulner-
ability to addiction will help us better understand ad-
dictions themselves.
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